Literature DB >> 13844958

Drug resistance in trapanososmes: cross-resitance analyses.

J WILLIAMSON, I M ROLLO.   

Abstract

Eight strains of Trypanosoma rhodesiense, made resistant respectively to atoxyl, butarsen, acriflavine, stilbamidine, Surfen C, suramin, and pontamine sky blue 5BX, have been examined for cross-resistance to representatives of nine structurally dissimilar groups of trypanocide. On the basis of their predominant ionic form at blood pH, these groups are considered in three main classes: (a) feebly ionized (neutral aromatic arsenicals), (b) ionized as cations (melaminyl arsenicals and antimonials, acridine derivatives, diguanidines and diamidines, 6-aminoquinoline and 6-aminocinnoline derivatives, phenanthridinium derivatives, triphenylmethane dyes), and (c) ionized as anions (carboxylated aromatic arsenicals and sulphonated naphthylamine derivatives). The results are discussed in relation to those of other workers and to possible modes of trypanocidal drug action. Cross-resistance behaviour is not wholly explicable on an ionic basis; the results suggest that stereospecific structural changes associated with initial drug uptake occur in resistant trypanosomes.

Entities:  

Keywords:  TRYPANOSOMA/pharmacology

Mesh:

Substances:

Year:  1959        PMID: 13844958      PMCID: PMC1481913          DOI: 10.1111/j.1476-5381.1959.tb00946.x

Source DB:  PubMed          Journal:  Br J Pharmacol Chemother        ISSN: 0366-0826


  8 in total

1.  The preparation of a strain of Trypanosoma rhodesiense resistant to stilbamidine and some observations on its nature.

Authors:  J D FULTON; P T GRANT
Journal:  Exp Parasitol       Date:  1955-07       Impact factor: 2.011

2.  Cross resistance of butarsen fast strains of T. equiperdum.

Authors:  R J SCHNITZER; A SCHUMACHER
Journal:  Arch Int Pharmacodyn Ther       Date:  1956-09-01

3.  Further studies on arsenic resistance in Trypanosoma gambiense.

Authors:  E J TOBIE; T VON BRAND
Journal:  Trans R Soc Trop Med Hyg       Date:  1954-09       Impact factor: 2.184

4.  Observations on the dehydrogenase activity of normal and drug-resistant strains of Trypanosoma rhodesiense.

Authors:  J WILLIAMSON
Journal:  Exp Parasitol       Date:  1953-10       Impact factor: 2.011

5.  A study of resistance to antrycide in a strain of Trypanosoma equiperdum.

Authors:  W E ORMEROD
Journal:  Br J Pharmacol Chemother       Date:  1952-12

6.  Trypanocidal action and toxicity to enzymes.

Authors:  J H Quastel
Journal:  Biochem J       Date:  1931       Impact factor: 3.857

7.  A cinnoline compound ("528") for the treatment of Trypanosoma congolense infections.

Authors:  E M LOURIE; J S MORLEY; J C E SIMPSON; J M WALKER
Journal:  Br J Pharmacol Chemother       Date:  1951-12

8.  Acquired resistance to 'Melarsen', tryparsamide and amidines in pathogenic trypanosomes after treatment with 'Melarsen' alone.

Authors:  I M ROLLO; J WILLIAMSON
Journal:  Nature       Date:  1951-01-27       Impact factor: 49.962

  8 in total
  3 in total

1.  In vitro and in vivo evaluation of 28DAP010, a novel diamidine for treatment of second-stage African sleeping sickness.

Authors:  Tanja Wenzler; Sihyung Yang; Donald A Patrick; Olivier Braissant; Mohamed A Ismail; Richard R Tidwell; David W Boykin; Michael Zhuo Wang; Reto Brun
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

2.  Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis.

Authors:  Tanja Wenzler; Sihyung Yang; Olivier Braissant; David W Boykin; Reto Brun; Michael Zhuo Wang
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

3.  The diamidine diminazene aceturate is a substrate for the high-affinity pentamidine transporter: implications for the development of high resistance levels in trypanosomes.

Authors:  Ibrahim A Teka; Anne J N Kazibwe; Nasser El-Sabbagh; Mohammed I Al-Salabi; Christopher P Ward; Anthonius A Eze; Jane C Munday; Pascal Mäser; Enock Matovu; Michael P Barrett; Harry P de Koning
Journal:  Mol Pharmacol       Date:  2011-03-24       Impact factor: 4.436

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.